The protective potentials of a potentized homeopathic
drug, Lycopodium-30, prepared from extract of spores of a plant, Lyocopodium clavatum (Fam: Lycopodiaceae) and used as a remedy for various liver ailments, have been tested in mice chronically fed p-dimethyl amino azo
benzene (p-DAB) - an initiator, and
phenobarbital (PB) - a promoter of
hepatic cancer, by using some cytogenetic endpoints like
chromosome aberrations (CA), micronuclei (MN), mitotic index (MI) and sperm head abnormality (SHA), and toxicity
biomarkers like
acid and alkaline
phosphatases (AcP and AlkP, respectively),
alanine and
aspartate amino
transferases (ALT and AST, respectively) and lipid peroxidation (LPO) and
reduced glutathione (GSH) activities. The effects of chronic treatment of the
carcinogens were assessed at different intervals of fixation, namely, at day 7, 15, 30, 60, 90 and day 120, and compared with that of mice fed conjointly with the
carcinogens and the homeopathic remedy. Both the assay systems indicated considerable protective potentials of the homeopathic remedy against p-DAB induced hepatocarcinogenesis in mice.